Clinical Trial Update: A Study of P38 Inhibitor (4) in Patients With Active Rheumatoid Arthritis (RA) on Stable Methotrexate Therapy [Phase 2]

View source ↗

Summary

A Phase 2 study of a P38 MAP kinase inhibitor (code 4) in rheumatoid arthritis patients on stable methotrexate has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• P38 inhibitor (4) (p38 MAP kinase inhibitor)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED